The initial euphoria over the GLP-1 drugs like Ozempic has mellowed, but catalysts expected in 2025 could energize investor interest in the stocks.
Related Posts
Dollar General shares jump 15% as discounter raises full-year forecast, shakes off tariff fears
Dollar General said it’s attracting more middle- and higher-income shoppers who are seeking value.
Elon Musk to travel to Wisconsin ahead of critical state Supreme Court election
Musk’s heavy political involvement in the battle for control of the Wisconsin Supreme Court has made him a central figure in the race.
The biggest questions facing Big Tech ahead of earnings
All of the megacap companies have significant exposure to President Donald Trump’s sweeping tariffs, which will be a major topic on earnings calls.